Download For patients with high risk DCIS, or with DCIS

“EARLY” BREAST CANCER
AXILLARY CONTROVERSIES
Edward J. White
FOR DCIS
For patients with large “high risk” DCIS, or with DCIS and
microinvasion, the probability of metastasis to axillary lymph nodes may be as
high as 10-12%. The significance of these reports is not defined because of
the known excellent results obtained historically in treating DCIS without
axillary node dissection. In a study of 76 patients with high risk DCIS and 31
with DCIS and microinvasion underwent SLN biopsy. 12 patients overall had
positive nodes. There were 9 in the pure high-risk group and 3 in the
microinvasion group. Nine of the overall positive group were found to have
micrometastases only. Six of the DCIS and 3 of the DCISM patients had
completion ALND and one of the DCIS patients had an additional positive
node. (Klauber-DeMore, Tan et al. 2000) A study at Moffitt of 87 patients with
pure DCIS was conducted with SLN and IHC techniques. Five of the 87
patients (6%) had positive nodes. Three of these patients were only IHC
positive and two were H&E positive. All SLNs that had only CK-positive cells
were subsequently confirmed malignant by a more detailed histological
examination of the nodes. Four of the patients with positive nodes had
comedocarcinoma and one had a 9.5 cm tumor with mixed micropapillary and
low grade cribriform. (Pendas, Dauway et al. 2000).
For small tumors (T1) with clinically a negative axilla, how useful is the sentinel
node biopsy, what is the therapeutic significance of axillary dissection, what do we
really learn from standard pathology, and what are the consequences of
occult/micrometastatic disease?
Standard treatment for small T1 tumors has a good outcome in general. In a
series of 962 patients (T1 to Small T2 N0-N1 M0) using standard pathology, those
patients with T1a and T1b lesion had a combined 15-year survival of 90%, whereas
those with T1c lesion dropped to 62%. Comparing node negative patients with node
positive patient the results were 84% vs. 31%. Local relapse occurred in only 3.4% (33
of 980 treated cases). All patients were treated by BCT, including wide local excision,
axillary dissection, postoperative radiation, and in the majority, adjuvant systemic
therapy.(Vitucci, Tirelli et al. 2000) When Danish data for tumors less than or equal to
10mm was analyzed for 4771 patients, there was noted to be significantly better survival
for those patients with 10 or more axillary nodes removed. They also noted that 8% of
the patients had 4 or more nodes positive for metastases. These patients were
retrospectively reviewed and had either mastectomy and ALND or BCT with ALND.
(Axelsson, Rank et al. 2000). .
1
A small Swiss study of 44 patients found a SLN 93 % of the time, with 21 patients
showing a positive SLN and 20 a negative node. One of the 20 had a positive node in
the ALND specimen (5%); negative predictive value 95%. Of 17 patients with positive
axillary nodes, only one had a negative SLN (5.9%) for a false negative rate of 5.9%.
Two of the 41 patients had IHC identification of micrometastases (9.5%). They also
noted that lymphoscintigraphy showed drainage to the internal mammary nodes in 2 of
28 patients (7%). (Langer, Zuber et al. 2000). For patients with invasive breast cancer,
peritumoral lymphovascular invasion was most accurate in predicting for false negative
sentinel nodes. (Noguchi, Kurosumi et al. 2000). Additional sections and special
staining both increase the percentages of metastases identified. In a multi-center study
of 214 node negative patients occult metastases were found in 15.9% of SLN and 4.2%
of non-sentinel nodes.(Weaver, Krag et al. 2000) Another study of ALND in 423 patients
with T1 lesions, showed a positive node in 1 of 31 T1a lesions (3%), 19 of 146 T1b (13%),
and 61 of 246 T1c (25%). The average age was 61 and no focused pathological analysis
was apparently used.(Lagares-Garcia, Garguilo et al. 2000). An Italian study of 102
patients with T1-T2 tumors showed a negative predictive value of 96.2% and a staging
accuracy of 97.7%. They used Isotope technique, injecting the day before surgery, and
found a sentinel node in 86.3% of the cases. Of 37 patients with positive axillary nodes
35 had positive SN (94.6% sensitivity), again a false negative rate of 5%. They also
noted that in over 50% of their cases the sentinel node was the only positive node.
(Casalegno, Sandrucci et al. 2000)
The question of recurrence after findings of negative lymph nodes is often
discussed. The failure to identify nodal metastases is used in some patients to eliminate
or downgrade subsequent adjuvant therapy, especially in small tumors. But around
thirty percent of node negative patients are reported to develop recurrence within 10
years. Various series have reported that retrospective serial sectioning of the lymph
nodes from these patients shows previously undetected metastases in 9-30% of the
cases. And the accuracy of standard pathology studies of the axillary nodes has been
studied many times. A recent study of 50 previously node negative patients showed a
10% micrometastasis by serial sectioning.(Karalak and Homcha-Em 1999). Another
study the SLN specimens of 52 patients with invasive breast cancer compared H & E
studies with serial sectioning and IHC staining. They found metastases in 12% of the
former and 58% of the later. The 24 patients with IHC detection were divided into 12
patients with isolated cells and 12 with colonies.(Dowlatshahi, Fan et al. 1999). In a
study of 736 patients with nodes negative by standard histology, occult nodal
metastases were detected by serial sectioning and hematoxylin and eosin staining in 52
(7%) and by immunohistochemistry in 148 (20%). Only two (3%) of 64 invasive lobular or
mixed invasive lobular and ductal cancers had node micrometastases detected by
hematoxylin and eosin, compared with 25 (39%) by immunohistochemistry. Occult
metastases, detected by either method, were associated with a significant decrease in
disease free and overall survival in postmenopausal but not in premenopausal patients.
Immunohistochemically detected occult lymph-node metastases remained an
independent and highly significant predictor of recurrence even after control for tumor
grade, tumor size, estrogen-receptor status, vascular invasion, and treatment
assignment. (Cote, Peterson et al. 1999). Another recent report looked at the predictive
2
factors for node metastases in 919 patients with T1a and T1b tumors. All patients
underwent ALND. There were 199 patients with T1a tumors and 720 with T1b tumors.
The overall incidence of metastases was 18%. Overall T1a metastasis was 16%(32 of
199). Overall T1b metastasis was 18.5%(133 of 720). These data were done on standard
H & E studies and level I and II ALND. They noted significant influence on risk by
patient age. For age > 50 the risk was 40 % less with small tumors. For patients < 40
the risk was 22.6% for T1a + T1B, but for > 70 years it was 10%. For tumors grade III the
risk was 2.5X greater than grade I. Lymphovascular invasion also correlated strongly
with increased risk of metastases. But even when they looked at patients with four
favorable factors (T1a, well differentiated, no lymphovascular invasion, and age greater
than 50), they found a 13% metastatic rate. For patients over 60 it dropped to 8.7%.
They stated that because there is no “subgroup of patients that had an acceptable low
risk of ALNM, the complete omission of assessing the axilla for metastatic disease in
patients with small breast cancers cannot be advocated”.(Rivadeneira, Simmons et al.
2000). In the commentary on this paper a group of 2185 patients treated at Brown with
tumors 1cm or less found a metastatic rate of 16% (11% for T1A and 17% for T1b). Age
was again a major factor with a 31% rate in <40 and 15% for older patients.(Mustafa,
Cole et al. 1997) In associating recurrence Rosen at Memorial Sloan Kettering in 1990
reviewed their data for patients treated 1964-1970 for tumors this size (1cm or less),
treated by mastectomy and ALND, and showed an 18-year recurrence rate of 12% with
mortality of 10% in node negative patients. This included 171 patients and the nodes
were studied by standard pathology. If the nodes were positive the recurrence rate was
39% and the mortality 35%.(Rosen and Groshen 1990)
Haigh has also shown that method of tumor biopsy (by excision, core or needle),
the volume of tissue removed and the timing of SLN biopsy do not affect the accuracy
of the SLN technique. In 284 patients, treated with SLN biopsy and completion ALND,
with a mean time of 17 days from tumor biopsy or excision to SLN biopsy they still
found the SLN over 80% of the time and the negative predictive value remained over
95% (the false negative rate was 3.2%). They also noted that over 50% of the time the
sentinel node was the only positive axillary node.(Haigh, Hansen et al. 2000)
It has also been shown that sentinel node biopsy is accurate and important
following neoadjuvant chemotherapy. In nearly 50% of the patients it is the only
positive node and it requires serial sectioning and IHC to identify 20% of the true
metastases.(Breslin, Cohen et al. 2000; Cohen, Breslin et al. 2000)
Some sentinel nodes are outside the axilla. In a study of 113 patients 19% were
found to have a sentinel node elsewhere. In only three cases was the nonaxillary node
the only sentinel node. Twenty-two of the 30 identified nonaxillay sentinel nodes were
harvested. Treatment changed in only three patients.(Jansen, Doting et al. 2000)
The risk of lymphedema is probably 20% with ALND and radiation therapy. It may
be one half this if ALND is eliminated. Substituting SLN biopsy for ALND markedly
reduces the early follow-up findings of lymphedema.(Schrenk, Rieger et al. 2000;
Tengrup, Tennvall-Nittby et al. 2000)
3
What are the implications of missed axillary metastases, occult and
micrometastatic? Multiple studies of node negative patients, re-reviewed for occult
metastases by serial sectioning and/or IHC, as well as prospective studies of
micrometastases, subsequently reviewed for outcome, have shown increased
recurrence and worsened survival in patients with occult and/or micrometastases.
These studies show a missed metastatic rate of 10 to 20 % and a reduction of disease
free survival of 10 to 20%.(Friedman, Bertin et al. 1988; 1990; de Mascarel, Bonichon et
al. 1992; Hainsworth, Tjandra et al. 1993) The data from the de Mascarel and Friedman
studies showed that even single micrometastases implied a significant increase in
recurrence.
What can be said about the potential benefit of axillary dissection with or without
the use of radiation therapy and/or chemotherapy? Axelsson suggested that their data
for T1a+T1 tumors implied a therapeutic advantage to axillary node dissection, with a
decrease in axillary recurrence and an increase in survival if 10 or more nodes were
removed. How radiation and chemotherapy were employed is not clear. (Axelsson, Rank
et al. 2000). An upper bound for local axillary recurrence may be obtained from the tenyear follow-up of the NSABP-B04 study. In spite of the probable 40% positive nodes in
the undissected patients, there was only a 17.8 % axillary failure rate in the non-treated
axilla (i.e. no radiation and no dissection). These patients underwent delayed axillary
dissection and ultimately only 4 of 365 patients failed in the axilla (1.1%).(Fisher,
Redmond et al. 1985). Giuliano’s series of sentinel node negative patients, treated with
no further axillary dissection, has shown no axillary recurrences in a 39-month mean
follow-up.(Giuliano, Haigh et al. 2000) It should also be noted that the majority of those
who did fail in the axilla in the NSABP study did so in the first 24 months. Osborne
studied 211 patients with T1 and T2 lesions with clinically negative nodes who did not
undergo axillary dissection, but had 6000 rads of external and interstitial radiation.
They found only three recurrences (1.4%).(Osborne, Ormiston et al. 1984). Another
study used to support the therapeutic value of axillary node dissection looked at 658
patients with T1 and T2 tumors. They were randomized to lumpectomy and radiation,
with or without axillary node dissection. There was an improvement in survival in those
who had axillary dissection, but only those who had pathologically proven disease on
ALND received chemotherapy or tamoxifen.(Cabanes, Salmon et al. 1992) Vitucci
establishes a lower bound for 15-year local/regional recurrence for standard BCT with
ALND/Rad RX and adjuvant RX at 3.4%.(Vitucci, Tirelli et al. 2000). Another study that
sought to clarify any survival benefit from axillary dissection combined results from six
randomized studies for a meta-analysis. They reported a 5.4% improvement in survival
with axillary dissection, however essentially no patients received adjuvant therapy and
there were unusually few T1a tumors in the series.(Orr 1999)
In a criticism of the recent Canadian and Danish studies that appear to support
the use of radiation to reduce locoregional recurrence in premenopausal high-risk
patients, Silberman found that the median number of nodes removed in those studies
was 7, compared to his 215 consecutive patients where the median number was 25. His
contention is that the benefit from radiation was really a compensation for inadequate
node removal. (Silberman, Sarna et al. 2000). Another study that looked at radiation
therapy after either no AND (292 patients) or limited (5 nodes or less) AN sampling (126
patients) with an 8 year follow-up, found 1.4% developed RNF (6 patients). Four had
4
simultaneous distant recurrence and 2 had isolated local recurrence. This study used
axillary and supraclavicular ports. (Galper, Recht et al. 2000). Wong et al, in a study of
76 patients T1 tumors treated by excision and two field tangential standard radiation
and no third nodal field, found no isolated nodal failure in a median 50 month followup.(Wong, Recht et al. 1997) Following up on this in a later paper studying 722 patients,
Wong et al found that lymphovascular invasion predicted a significant increased risk of
greater than four positive axillary nodes. They proposed that this might allow
distinction between those who require addition of a third field for
axillary/supraclavicular radiation.(Wong, O'Neill et al. 2000)
The success or failure of radiation therapy may depend considerably on the intact
apoptotic pathway. This pathway is largely dependant on p53 and its related signaling
proteins. These elements are damaged in a high percentage of breast cancers. It
appears that identification of these abnormalities may predict radioresistence.(DahmDaphi 2000)
Kuerer et al showed the effect of chemotherapy on known positive axillary nodes
in a study. Of 191 patients with locally advanced disease and cytologically proven
axillary nodal metastases who were treated with neoadjuvant therapy, 23% were
converted to a histologically negative axilla on subsequent AND. The lymph nodes
from these 43 patients were studied with serial sectioning and IHC and only 4 (10%)
were found to have occult metastases. Five-year survival was 87% in patients with preoperative eradication of nodal disease and 51% on those with residual disease (it was
75% in those with occult residual disease).(Kuerer, Sahin et al. 1999) So it is probable
that chemotherapy and radiation therapy can have a marked effect on the non-dissected
axilla.
The question of the internal mammary nodes is also an issue. A recent
prospective study of 80 consecutive patients showed that 12% had an identified IMSLN
in addition to an axillary SLN.(Johnson, Soot et al. 2000) All patients underwent ALND
and sentinel node biopsy. The quadrant did not predict well the presence of an IMSLN;
60% of the cases with a sentinel IM node were from lateral lesions. Metastatic disease
was found in 3 of the 10 IMSLN cases, but all of these had positive axillary nodes. It is
unclear whether they used IHC, but they did comment on historical data that showed in
T1 and T2 tumors around 7% of nodal metastases may be isolated to the IM nodes.
However, this data predated the more focused techniques of SLN evaluation by intense
pathology and IHC now available. Numerous studies and reviews have failed to show
any survival benefit in assessment or treatment of the internal mammary nodes.
(Donegan 1977; Fisher, Redmond et al. 1985; Fowble, Hanlon et al. 2000; Freedman,
Fowble et al. 2000; Sugg, Ferguson et al. 2000) An excellent review article on adjuvant
radiation therapy for breast cancer supports the findings that there is a significant
reduction in locoregional failure but that overall survival is not improved, largely
because of the late cardiotoxicity. Without adjuvant radiation therapy, in node positive
patients, the risk of locoregional failure at 10 years was 25% with 1-3 positive axillary
nodes, and rose to 55% with 10 or more positive nodes. With radiation those
recurrence rates dropped to 8% and 20% respectively.(Arriagada and Le 2000)
5
EXPLORING THE PROBABILITIES
ASSUME
1000 pts
negative
Negative SLN
1000 pts
eval by
SLN vs ALND
1000 pts
T1a+T1b
Standard Path
By SLN
But with SLN and
SS and IHC
IF
95%
Correct
Find
5-10%
(Missed at
standard Path)
20% + Nodes
THEN
5%
False Neg
RESULTANT
Missed
50 Pts
Gained
50 Pts
200 pts
+ nodes
Get
95%
of the 200
Get add’l
10% of
remaining
800
200 pts
+ nodes
detected
190 pts
80 pts
Allow for only
Finding 90% SLN
90% of 270 +
243 pts
For 1000
untreated
axillae
Minimum 25%
250 patients
positive (40%
Max)*
180 *?*
axillary
recurrences
18% of 1000
(NSABP)
Assume prior
Chemo+Rad
Recruits salvage in
Similar 1000 pts
In 50% of cases
+SLN is only
positive axillary
node
Assume 50%
benefit
1000 pts
Assume 20%+
200+
100+ single
THEREFORE
900 pts
ALND adds
Nothing
Dx or Rx
190 +80=
270 pts
Potential
Detected
+ nodes
243 patients
243-200=
+ nodes
43 Extra pts
Detected
Node+ with
SLN vs Reg Path
Less
Less
Than 10%
Than
Fail delayed
18 pts fail
Rx
sequence
No ALND
+ Salvage
Less
Than
9 pts Fail after
no ALND+Rx
Potential for
Benefit to
Only 10 % Max
6
AXILLARY AXIOMS
1) There is a subset of patients with small tumors and negative axillary nodes
who have dissemination and are non-salvageable by maximum current
therapy. (2-5%)
2) There is a persistent local failure rate that is not preventable by the maximum
current therapy of mastectomy+ALND+chemo+radiation.
3) No randomized study shows a survival benefit to axillary dissection.
4) Delayed treatment of axillary nodes provides equivalent local control and
survival benefit.
5) Treatment of the axilla reduces the risk of local recurrence, but does not
improve overall survival.
6) Axillary dissection with removal of >10 lymph nodes may improve the
recurrence free survival but not overall survival.
7) The axillary failure rate in clinically node negative patients, untreated by
dissection, chemotherapy, or radiation is one-half the known metastatic rate
(20% vs. 40%).
8) Standard pathology of the axillary nodes misses at least 10% of nodal
metastases.
9) If knowledge of node status changes treatment recommendations, then you
cannot rely on traditional pathology, especially with lobular carcinoma. (i.e. if
you change the chemo rx based on positive or negative nodes).
10) New “Standard” requires SLN identification even if pre-decided on level I and
II ALND, if micrometastasis would imply alteration of chemorx.
11) Sentinel node biopsy, though unsuccessful in 10% of patients, and false
negative in 10% of patients, still provides an approximate 20% gain in the
identification of axillary metastases over level l and ll ALND and standard
pathology.
12) In 50% of cases a positive SLN is the only positive axillary node.
13) Chemotherapy can convert a positive axilla to microscopically negative,
probably 25% of the time.
14) Standard breast radiation, which treats the lower axilla by serendipity,
markedly reduces the risk of axillary nodal failure, in clinically node negative
patients who do not undergo axillary dissection.
15) Micrometastases or occult metastases, identified by whatever technique
identify patients at significant risk of dying from metastatic disease.
16) Formal radiation therapy, directed to the axilla and supraclavicular fossa,
markedly reduces the risk of regional nodal failure.
17) The great majority of patients with internal mammary node metastases have
identifiable axillary metastases.
18) Randomized studies investigating the potential benefit of treatments by
surgery or radiation, directed at the internal mammary nodes do not show any
survival benefit.
19) Lymphovascular invasion, age less than 40, multifocality, and invasive lobular
carcinoma make IHC studies essential and increase the relative risk of false
negative SLN and multiple positive nodes.
7
20) The patient < 40 with a bad histology, LVI, and invasive lobular represents a
worst case for eliminating ALND even in T1 tumors; if a sentinel node cannot
be found ALND is essential.
21) Her2/neu amplification and/or overexpression may identify increased risk of
disseminated disease in truly node negative patients.
22) Location (quadrant) does not significantly affect the importance of the internal
mammary nodes, or the benefit of SLN biopsy.
23) If it is justifiable to include a supraclavicular field for radiation therapy for the
non-dissected axilla, then it should be added to the dissected axilla.
24) DCIS “high risk” of large size or microinvasion require SLN biopsy.
25) Even in small tumors (T1a-T1b) the risk of metastasis is at least 16% and in
young patients it may be 30%. The risk of multiple positive nodes is 8%.
26) The risk of significant lymphedema is worse with combination of axillary
dissection and radiation than with either modality alone.
27) Therapeutic radiation alone to the axilla and supraclavicular fossa has at least
a 5% risk of lymphedema without axillary dissection.
28) The success of radiation depends on a competent apoptotic pathway. P53
overexpression (abnormal protein) and related apoptosis pathway failure
predicts for radiation failure.
29) Axillary evaluation requires axillary ultrasound, and completion of breast
work-up.
30) Sentinel node biopsy is still valuable after neoadjuvant therapy or prior tumor
excision.
31) To recommend that more surgery (e.g. completion ALND) should be done for
any given tumor we need to show at least one of the following: 1) That there is
an identifiable primary benefit from the procedure. 2) That negative findings
will eliminate the need for treatments with the potential for serious side
effects. 3) That positive findings will introduce additional therapies that will
improve recurrence free or overall survival.
(1990). “Prognostic importance of occult axillary lymph node micrometastases
from breast cancers. International (Ludwig) Breast Cancer Study Group [see
comments].” Lancet 335(8705): 1565-8.
Arriagada, R. and M. G. Le (2000). “Adjuvant radiotherapy in breast cancer--the
treatment of lymph node areas.” Acta Oncol 39(3): 295-305.
Axelsson, C. K., F. Rank, et al. (2000). “Impact of axillary dissection on staging
and regional control in breast tumors or = 10 mm--the DBCG experience. The Danish
Breast Cancer Cooperative Group (DBCG), Rigshisoutalet, Copenhagen, Denmark.”
Acta Oncol 39(3): 283-9.
Breslin, T. M., L. Cohen, et al. (2000). “Sentinel lymph node biopsy is accurate
after neoadjuvant chemotherapy for breast cancer [In Process Citation].” J Clin
Oncol 18(20): 3480-6.
8
Cabanes, P. A., R. J. Salmon, et al. (1992). “Value of axillary dissection in
addition to lumpectomy and radiotherapy in early breast cancer. The Breast
Carcinoma Collaborative Group of the Institut Curie [see comments].” Lancet
339(8804): 1245-8.
Casalegno, P. S., S. Sandrucci, et al. (2000). “Sentinel lymph node and breast
cancer staging: final results of the Turin Multicenter Study [In Process Citation].”
Tumori 86(4): 300-3.
Cohen, L. F., T. M. Breslin, et al. (2000). “Identification and evaluation of
axillary sentinel lymph nodes in patients with breast carcinoma treated with
neoadjuvant chemotherapy.” Am J Surg Pathol 24(9): 1266-72.
Cote, R. J., H. F. Peterson, et al. (1999). “Role of immunohistochemical
detection of lymph-node metastases in management of breast cancer. International
Breast Cancer Study Group [see comments].” Lancet 354(9182): 896-900.
Dahm-Daphi, J. (2000). “p53: biology and role for cellular radiosensitivity.”
Strahlenther Onkol 176(6): 278-85.
de Mascarel, I., F. Bonichon, et al. (1992). “Prognostic significance of breast
cancer axillary lymph node micrometastases assessed by two special techniques:
reevaluation with longer follow-up.” Br J Cancer 66(3): 523-7.
Donegan, W. L. (1977). “The influence of untreated internal mammary
metastases upon the course of mammary cancer.” Cancer 39(2): 533-8.
Dowlatshahi, K., M. Fan, et al. (1999). “Occult metastases in the sentinel lymph
nodes of patients with early stage breast carcinoma: A preliminary study [see
comments].” Cancer 86(6): 990-6.
Fisher, B., C. Redmond, et al. (1985). “Ten-year results of a randomized clinical
trial comparing radical mastectomy and total mastectomy with or without radiation.”
N Engl J Med 312(11): 674-81.
Fowble, B., A. Hanlon, et al. (2000). “Internal mammary node irradiation neither
decreases distant metastases nor improves survival in stage I and II breast cancer.”
Int J Radiat Oncol Biol Phys 47(4): 883-94.
Freedman, G. M., B. L. Fowble, et al. (2000). “Should internal mammary lymph
nodes in breast cancer be a target for the radiation oncologist? [see comments].” Int
J Radiat Oncol Biol Phys 46(4): 805-14.
Friedman, S., F. Bertin, et al. (1988). “Importance of tumor cells in axillary node
sinus margins ('clandestine' metastases) discovered by serial sectioning in operable
breast carcinoma.” Acta Oncol 27(5): 483-7.
Galper, S., A. Recht, et al. (2000). “Is radiation alone adequate treatment to the
axilla for patients with limited axillary surgery? Implications for treatment after a
positive sentinel node biopsy.” Int J Radiat Oncol Biol Phys 48(1): 125-32.
Giuliano, A. E., P. I. Haigh, et al. (2000). “Prospective observational study of
sentinel lymphadenectomy without further axillary dissection in patients with
sentinel node-negative breast cancer.” J Clin Oncol 18(13): 2553-9.
Haigh, P. I., N. M. Hansen, et al. (2000). “Biopsy method and excision volume
do not affect success rate of subsequent sentinel lymph node dissection in breast
cancer.” Ann Surg Oncol 7(1): 21-7.
Hainsworth, P. J., J. J. Tjandra, et al. (1993). “Detection and significance of
occult metastases in node-negative breast cancer.” Br J Surg 80(4): 459-63.
9
Jansen, L., M. H. Doting, et al. (2000). “Clinical relevance of sentinel lymph
nodes outside the axilla in patients with breast cancer.” Br J Surg 87(7): 920-5.
Johnson, N., L. Soot, et al. (2000). “Sentinel node biopsy and internal
mammary lymphatic mapping in breast cancer.” Am J Surg 179(5): 386-8.
Karalak, A. and P. Homcha-Em (1999). “Occult axillary lymph node metastases
discovered by serial section in node-negative breast cancer.” J Med Assoc Thai
82(10): 1017-9.
Klauber-DeMore, N., L. K. Tan, et al. (2000). “Sentinel lymph node biopsy: is it
indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-insitu with microinvasion? [In Process Citation].” Ann Surg Oncol 7(9): 636-42.
Kuerer, H. M., A. A. Sahin, et al. (1999). “Incidence and impact of documented
eradication of breast cancer axillary lymph node metastases before surgery in
patients treated with neoadjuvant chemotherapy.” Ann Surg 230(1): 72-8.
Lagares-Garcia, J. A., G. Garguilo, et al. (2000). “Axillary lymph node
dissection in breast cancer: an evolving question?” Am Surg 66(1): 66-72.
Langer, I., M. Zuber, et al. (2000). “[Validation study of the sentinel lymph node
(SLN) method in invasive breast carcinoma. Personal data and review of the
literature].” Swiss Surg 6(3): 128-36.
Mustafa, I. A., B. Cole, et al. (1997). “The impact of histopathology on nodal
metastases in minimal breast cancer.” Arch Surg 132(4): 384-90; discussion 390-1.
Noguchi, M., M. Kurosumi, et al. (2000). “Clinical and Pathologic Factors
Predicting Axillary Lymph Node Involvement in Breast Cancer.” Breast Cancer 7(2):
114-123.
Orr, R. K. (1999). “The impact of prophylactic axillary node dissection on
breast cancer survival--a Bayesian meta-analysis [see comments].” Ann Surg Oncol
6(1): 109-16.
Osborne, M. P., N. Ormiston, et al. (1984). “Breast conservation in the
treatment of early breast cancer. A 20-year follow-up.” Cancer 53(2): 349-55.
Pendas, S., E. Dauway, et al. (2000). “Sentinel node biopsy in ductal carcinoma
in situ patients.” Ann Surg Oncol 7(1): 15-20.
Rivadeneira, D. E., R. M. Simmons, et al. (2000). “Predictive factors associated
with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in
more than 900 patients.” J Am Coll Surg 191(1): 1-6; discussion 6-8.
Rosen, P. P. and S. Groshen (1990). “Factors influencing survival and
prognosis in early breast carcinoma (T1N0M0-T1N1M0). Assessment of 644 patients
with median follow-up of 18 years.” Surg Clin North Am 70(4): 937-62.
Schrenk, P., R. Rieger, et al. (2000). “Morbidity following sentinel lymph node
biopsy versus axillary lymph node dissection for patients with breast carcinoma.”
Cancer 88(3): 608-14.
Silberman, A. W., G. P. Sarna, et al. (2000). “Adjuvant radiation trials for highrisk breast cancer patients: adequacy of lymphadenectomy [In Process Citation].”
Ann Surg Oncol 7(5): 357-60.
Sugg, S. L., D. J. Ferguson, et al. (2000). “Should internal mammary nodes be
sampled in the sentinel lymph node era?” Ann Surg Oncol 7(3): 188-92.
Tengrup, I., L. Tennvall-Nittby, et al. (2000). “Arm morbidity after breastconserving therapy for breast cancer.” Acta Oncol 39(3): 393-7.
10
Vitucci, C., C. Tirelli, et al. (2000). “Results of conservative surgery for limitedsized infiltrating breast cancer: analysis of 962 tested patients: 24 years of
experience.” J Surg Oncol 74(2): 108-15.
Weaver, D. L., D. N. Krag, et al. (2000). “Pathologic analysis of sentinel and
nonsentinel lymph nodes in breast carcinoma: a multicenter study [see comments].”
Cancer 88(5): 1099-107.
Wong, J. S., A. O'Neill, et al. (2000). “The relationship between lymphatic
vessell invasion, tumor size, and pathologic nodal status: can we predict who can
avoid a third field in the absence of axillary dissection?” Int J Radiat Oncol Biol Phys
48(1): 133-7.
Wong, J. S., A. Recht, et al. (1997). “Treatment outcome after tangential
radiation therapy without axillary dissection in patients with early-stage breast
cancer and clinically negative axillary nodes.” Int J Radiat Oncol Biol Phys 39(4):
915-20.
11